Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Abiraterone and increased survival in metastatic prostate cancer.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators..

N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.

2.

Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.

Molina A, Belldegrun A.

J Urol. 2011 Mar;185(3):787-94. doi: 10.1016/j.juro.2010.10.042. Epub 2011 Jan 15. Review. Erratum in: J Urol. 2011 Aug;186(2):762.

PMID:
21239012
3.

Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1.

Mast N, Annalora AJ, Lodowski DT, Palczewski K, Stout CD, Pikuleva IA.

J Biol Chem. 2011 Feb 18;286(7):5607-13. doi: 10.1074/jbc.M110.188433. Epub 2010 Dec 15.

4.

CYP17 inhibitors for prostate cancer therapy.

Vasaitis TS, Bruno RD, Njar VC.

J Steroid Biochem Mol Biol. 2011 May;125(1-2):23-31. doi: 10.1016/j.jsbmb.2010.11.005. Epub 2010 Nov 17. Review.

5.

The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Miller WL, Auchus RJ.

Endocr Rev. 2011 Feb;32(1):81-151. doi: 10.1210/er.2010-0013. Epub 2010 Nov 4. Review. Erratum in: Endocr Rev. 2011 Aug;32(4):579.

6.

Molecular modeling on inhibitor complexes and active-site dynamics of cytochrome P450 C17, a target for prostate cancer therapy.

Haider SM, Patel JS, Poojari CS, Neidle S.

J Mol Biol. 2010 Jul 30;400(5):1078-98. doi: 10.1016/j.jmb.2010.05.069. Epub 2010 Jun 2.

PMID:
20595043
7.

Clinical, genetic and functional characteristics of three novel CYP17A1 mutations causing combined 17alpha-hydroxylase/17,20-lyase deficiency.

Rosa S, Steigert M, Lang-Muritano M, l'Allemand D, Schoenle EJ, Biason-Lauber A.

Horm Res Paediatr. 2010;73(3):198-204. doi: 10.1159/000284362. Epub 2010 Mar 3.

PMID:
20197673
8.

Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

Huang P, Chandra V, Rastinejad F.

Annu Rev Physiol. 2010;72:247-72. doi: 10.1146/annurev-physiol-021909-135917. Review.

9.

A single amino acid residue, Ala 105, confers 16alpha-hydroxylase activity to human cytochrome P450 17alpha-hydroxylase/17,20 lyase.

Swart AC, Storbeck KH, Swart P.

J Steroid Biochem Mol Biol. 2010 Apr;119(3-5):112-20. doi: 10.1016/j.jsbmb.2009.12.014. Epub 2010 Jan 4.

PMID:
20043997
10.

Novel CYP17A1 mutation in a Japanese patient with combined 17alpha-hydroxylase/17,20-lyase deficiency.

Katsumata N, Ogawa E, Fujiwara I, Fujikura K.

Metabolism. 2010 Feb;59(2):275-8. doi: 10.1016/j.metabol.2009.07.024. Epub 2009 Sep 29.

PMID:
19793597
11.

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Attard G, Reid AH, Olmos D, de Bono JS.

Cancer Res. 2009 Jun 15;69(12):4937-40. doi: 10.1158/0008-5472.CAN-08-4531. Epub 2009 Jun 9. Review.

12.

Novel P450c17 mutation H373D causing combined 17alpha-hydroxylase/17,20-lyase deficiency.

Sahakitrungruang T, Tee MK, Speiser PW, Miller WL.

J Clin Endocrinol Metab. 2009 Aug;94(8):3089-92. doi: 10.1210/jc.2009-0645. Epub 2009 May 26.

PMID:
19470621
13.

Steroid 17alpha-hydroxylase deficiency: functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene.

Dhir V, Reisch N, Bleicken CM, Lebl J, Kamrath C, Schwarz HP, Grötzinger J, Sippell WG, Riepe FG, Arlt W, Krone N.

J Clin Endocrinol Metab. 2009 Aug;94(8):3058-64. doi: 10.1210/jc.2009-0172. Epub 2009 May 19.

PMID:
19454579
14.

Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes.

DeVore NM, Smith BD, Wang JL, Lushington GH, Scott EE.

Drug Metab Dispos. 2009 Jun;37(6):1319-27. doi: 10.1124/dmd.109.026765. Epub 2009 Feb 27.

15.

Structural basis for androgen specificity and oestrogen synthesis in human aromatase.

Ghosh D, Griswold J, Erman M, Pangborn W.

Nature. 2009 Jan 8;457(7226):219-23. doi: 10.1038/nature07614.

16.

The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.

Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G.

Urol Oncol. 2009 Jan-Feb;27(1):53-63. doi: 10.1016/j.urolonc.2008.07.036. Review.

17.

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM.

Mol Cancer Ther. 2008 Aug;7(8):2348-57. doi: 10.1158/1535-7163.MCT-08-0230.

18.

Engineering, expression, and purification of "soluble" human cytochrome P45017alpha and its functional characterization.

Pechurskaya TA, Lukashevich OP, Gilep AA, Usanov SA.

Biochemistry (Mosc). 2008 Jul;73(7):806-11.

19.

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.

J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.

PMID:
18645193
20.

Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.

Mast N, White MA, Bjorkhem I, Johnson EF, Stout CD, Pikuleva IA.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9546-51. doi: 10.1073/pnas.0803717105. Epub 2008 Jul 9.

Supplemental Content

Support Center